CA2002144A1 - Methode de prevention ou de reduction de l'eosinophilie - Google Patents

Methode de prevention ou de reduction de l'eosinophilie

Info

Publication number
CA2002144A1
CA2002144A1 CA2002144A CA2002144A CA2002144A1 CA 2002144 A1 CA2002144 A1 CA 2002144A1 CA 2002144 A CA2002144 A CA 2002144A CA 2002144 A CA2002144 A CA 2002144A CA 2002144 A1 CA2002144 A1 CA 2002144A1
Authority
CA
Canada
Prior art keywords
preventing
antagonist
reducing eosinophilia
human interleukin
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2002144A
Other languages
English (en)
Other versions
CA2002144C (fr
Inventor
Robert L. Coffman
Donna M. Rennick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23016493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2002144(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2002144A1 publication Critical patent/CA2002144A1/fr
Application granted granted Critical
Publication of CA2002144C publication Critical patent/CA2002144C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Optical Head (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pens And Brushes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Lubricants (AREA)
CA002002144A 1988-11-03 1989-11-02 Methode de prevention ou de reduction de l'eosinophilie Expired - Lifetime CA2002144C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26690988A 1988-11-03 1988-11-03
US266,909 1988-11-03

Publications (2)

Publication Number Publication Date
CA2002144A1 true CA2002144A1 (fr) 1990-05-03
CA2002144C CA2002144C (fr) 2000-03-28

Family

ID=23016493

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002002144A Expired - Lifetime CA2002144C (fr) 1988-11-03 1989-11-02 Methode de prevention ou de reduction de l'eosinophilie

Country Status (17)

Country Link
EP (2) EP0367596B1 (fr)
JP (1) JPH07563B2 (fr)
KR (1) KR960002183B1 (fr)
AT (1) ATE98872T1 (fr)
AU (1) AU633034B2 (fr)
CA (1) CA2002144C (fr)
DE (1) DE68911653T2 (fr)
DK (1) DK81691D0 (fr)
ES (1) ES2062032T3 (fr)
HK (1) HK186196A (fr)
IE (1) IE63063B1 (fr)
IL (1) IL92180A (fr)
MY (1) MY107386A (fr)
NZ (1) NZ243939A (fr)
PH (1) PH26476A (fr)
WO (1) WO1990004979A2 (fr)
ZA (1) ZA898322B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT67943A (en) * 1992-02-06 1995-05-29 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
WO1994017773A2 (fr) * 1993-02-01 1994-08-18 Université Libre de Bruxelles Utilisation d'une composition pharmaceutique comprenant une dose efficace d'interleukine-10, d'un analogue et/ou d'un agoniste d'interleukine-10
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
CA2208503C (fr) * 1994-12-23 2009-12-01 Smithkline Beecham P.L.C. Antagonistes de recombinaison de l'il-5 utiles dans le traitement des troubles induits par l'il-5
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
PT1527100E (pt) 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
JP5917143B2 (ja) 2008-03-28 2016-05-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 処置方法
BR112019025736A2 (pt) 2017-06-06 2020-06-30 Glaxosmithkline Llc uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359783B2 (fr) * 1987-06-24 2002-04-17 Autoimmune, Inc. Traitement de maladies auto-immunitaires par administration orale d'auto-antigenes

Also Published As

Publication number Publication date
CA2002144C (fr) 2000-03-28
DE68911653D1 (de) 1994-02-10
JPH03505211A (ja) 1991-11-14
DK81691A (da) 1991-05-02
DE68911653T2 (de) 1994-04-07
NZ243939A (en) 1997-07-27
HK186196A (en) 1996-10-11
MY107386A (en) 1995-11-30
WO1990004979A2 (fr) 1990-05-17
KR960002183B1 (ko) 1996-02-13
IE63063B1 (en) 1995-03-22
IE893525L (en) 1990-05-03
KR900701320A (ko) 1990-12-01
ZA898322B (en) 1990-11-28
ATE98872T1 (de) 1994-01-15
IL92180A (en) 1997-04-15
EP0367596A1 (fr) 1990-05-09
AU4644889A (en) 1990-05-28
AU633034B2 (en) 1993-01-21
ES2062032T3 (es) 1994-12-16
DK81691D0 (da) 1991-05-02
EP0367596B1 (fr) 1993-12-22
IL92180A0 (en) 1990-07-26
EP0441891A1 (fr) 1991-08-21
JPH07563B2 (ja) 1995-01-11
PH26476A (en) 1992-07-27
WO1990004979A8 (fr) 2005-06-16

Similar Documents

Publication Publication Date Title
AU3038389A (en) Method of reducing immunoglobulin e responses
EP0597829A4 (fr) Nouvel anticorps monoclonal dresse contre un nouvel antigene associe aux tumeurs humaines.
AU4688589A (en) A method for treatment of endotoxic shock in a mammal
SG42954A1 (en) Antibody to human interleukin-6 receptor
GB2185266B (en) Monoclonal antibodies cross-reactive and cross-protective against p. aeruginosa serotypes
AU4493685A (en) Polyclonal antibodies, preparation and use
EP0312996A3 (en) Anti-human bcdf monoclonal antibody
WO1990004979A8 (fr) Procede de prevention et de reduction de l'eosinophilie
EP0216454A3 (en) Method of promoting animal growth
GB2186592B (en) Cross-protective human monoclonal antibody compositions
EP0341684A3 (en) Human monoclonal antibody, hybridoma producing the same and pharmaceutical
WO1991007986A8 (fr) Methode de traitement de choc septique
AU6596390A (en) Monoclonal antibodies cross-reactive and cross-protective against p. aeruginosa serotypes
ZA912138B (en) Bcrf1 antagonists for treating epstein-barr virus infections
CS792587A1 (en) Mouse lymphocytaric hybridom producing antibody against human alpha-fetoproteine
AU3987589A (en) Antibody to p. falciparum antigen and hybridoma for making same
EP0407430A4 (en) Therapeutic murine monoclonal antibody
CS495286A1 (en) Mouse lymhocytaric hybridom producing antibody against human choriogonadotropic hormone
CS101189A1 (en) Img-czas afp-15 murine lymphocyte hybridoma producing antibody against human alpha-foetoprotein

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry